Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization
- PMID: 25045002
- PMCID: PMC4804463
- DOI: 10.1002/lt.23945
Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization
Abstract
Liver transplantation (LT) is the treatment of choice for patients with cirrhosis and hepatocellular carcinoma (HCC) not amenable to resection. Locoregional therapies for HCC are often used to reduce tumor burden, bridge patients to LT, and down-stage HCC so that patients are eligible for LT. We hypothesized that prior endovascular antitumor therapy may increase the risk of hepatic artery (HA) and biliary complications after LT. The aim of this study was to compare HA and biliary complications in LT recipients with HCC who received transarterial chemoembolization (TACE) before LT with complications in LT recipients with HCC who did not receive TACE before LT. This was a retrospective cohort study of HCC patients at two transplant centers. The prevalence of HA complications (HA thrombosis, stenosis, or pseudoaneurysm) and biliary complications (nonanastomotic stricture, bile leak, and diffuse injury) were compared between patients treated with or without TACE. There were 456 HCC patients with a median age of 61 years (77% were male, and 63% had hepatitis C virus), and 328 (72%) received TACE before LT. The overall prevalence of HA complications was 4.7% in the no-TACE group and 7.9% in the TACE group (P = 0.22). All HA stenosis complications (n = 14) occurred in the TACE group (P = 0.018 versus the no-TACE group). An older donor age and a lower albumin level significantly increased the odds of HA complications. There was a nonstatistically significant increased odds of HA complications in the TACE group versus the no-TACE group according to an adjusted analysis (odds ratio = 2.02, 95% confidence interval = 0.79-5.16, P = 0.14). The overall prevalence of biliary complications was 16.4% in the no-TACE group and 19.8% in the TACE group (P = 0.40). In conclusion, a lower pre-LT albumin level and an older donor age were significantly associated with higher odds of HA complications after LT. TACE was not associated with higher odds of overall HA complications but was associated with a higher prevalence of HA stenosis. Further studies are warranted to confirm the HA stenosis findings and elucidate the pathogenesis.
© 2014 American Association for the Study of Liver Diseases.
Figures
Comment in
-
Transarterial chemoembolization and radiological vascular complications.Liver Transpl. 2015 Mar;21(3):415. doi: 10.1002/lt.24046. Epub 2015 Jan 12. Liver Transpl. 2015. PMID: 25408435 No abstract available.
-
Reply: To PMID 25045002.Liver Transpl. 2015 Mar;21(3):416. doi: 10.1002/lt.24066. Epub 2015 Jan 26. Liver Transpl. 2015. PMID: 25530165 No abstract available.
-
Transarterial chemoembolization does not harm the hepatic artery at transplantation.Liver Transpl. 2015 Apr;21(4):564. doi: 10.1002/lt.24067. Epub 2015 Jan 26. Liver Transpl. 2015. PMID: 25545369 No abstract available.
References
-
- Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513–521. - PubMed
-
- Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51:1820–1832. - PubMed
-
- Bruix J, Sherman M, for Practice Guidelines Committee of the American Association for the Study of Liver Diseases Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236. - PubMed
-
- Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–338. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous